22,304 Thermo Fisher Scientific Inc. $TMO Shares Sold by Canoe Financial LP

Key Points

• Canoe Financial reduced its Thermo Fisher stake by 7.2%, selling 22,304 shares and retaining 287,690 shares valued at approximately $187.7 million. Institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported better-than-expected third-quarter results, with revenue rising 9% to $12.14 billion and adjusted EPS increasing 15% to $6.68. Management also raised its 2026 growth and earnings outlook.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and an average price target of $657.57, although the stock recently traded near its 12-month high and faced some defensive options activity.

Canoe Financial LP trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 7.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 287,690 shares of the medical research company's stock after selling 22,304 shares during the period. Thermo Fisher Scientific comprises about 2.3% of Canoe Financial LP's portfolio, making the stock its 12th largest position. Canoe Financial LP owned about 0.08% of Thermo Fisher Scientific worth $187,721,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. Tsfg LLC raised its position in Thermo Fisher Scientific by 20.4% in the 2nd quarter. Tsfg LLC now owns 112 shares of the medical research company's stock valued at $56,000 after buying an additional 19 shares during the last quarter. Renasant Bank raised its holdings in shares of Thermo Fisher Scientific by 1.0% in the second quarter. Renasant Bank now owns 1,934 shares of the medical research company's stock valued at $970,000 after purchasing an additional 20 shares during the last quarter. Strengthening Families & Communities LLC raised its holdings in shares of Thermo Fisher Scientific by 0.4% in the third quarter. Strengthening Families & Communities LLC now owns 4,721 shares of the medical research company's stock valued at $3,187,000 after purchasing an additional 21 shares during the last quarter. TCI Wealth Advisors Inc. lifted its position in shares of Thermo Fisher Scientific by 5.4% in the first quarter. TCI Wealth Advisors Inc. now owns 431 shares of the medical research company's stock worth $212,000 after purchasing an additional 22 shares in the last quarter. Finally, Legacy Wealth Managment LLC ID boosted its holdings in Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock worth $25,000 after purchasing an additional 22 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 420 shares of the firm's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares of the company's stock, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 275 shares of Thermo Fisher Scientific stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the sale, the chief executive officer owned 123,925 shares of the company's stock, valued at $77,707,171.25. This trade represents a 0.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,768 shares of company stock worth $44,122,820 over the last ninety days. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific News Summary

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Quarterly results exceeded expectations. Thermo Fisher reported revenue of $12.14 billion, up 9% year over year and above the roughly $11.95 billion consensus estimate. Adjusted EPS rose 15% to $6.68, beating expectations of $6.40. Thermo Fisher Scientific Reports Third Quarter 2026 Results
• Positive Sentiment: Organic growth and margins improved. Organic revenue growth reached 6%, driven by stronger customer activity in clinical research, bioproduction and laboratory products. Operating margin expanded to 24.5%, aided by process improvements, acquisitions and divestitures. Thermo Fisher: You Don't Need A Microscope To See The Growth Anymore
• Positive Sentiment: Management raised its full-year outlook. Thermo Fisher lifted its 2026 organic revenue-growth forecast to 4% while increasing full-year earnings and revenue guidance, reinforcing expectations for continued recovery. Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: Trading was volatile: despite the earnings beat, shares initially fell in premarket trading before reversing higher. This suggests some investors may have been seeking an even stronger outlook or were taking profits after the recent rally. TMO Q3 Earnings and Revenues Beat Estimates
• Negative Sentiment: Unusually high put-option activity indicates that some traders were positioned defensively, although this does not necessarily reflect the company’s fundamentals.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, October 3rd. Scotiabank started coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, September 9th. They set an "outperform" rating on the stock. Piper Sandler assumed coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, September 9th. They set an "overweight" rating for the company. Stifel Nicolaus set a $650.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, August 5th. Finally, Wells Fargo & Company cut Thermo Fisher Scientific from an "overweight" rating to an "underweight" rating in a report on Wednesday, September 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus target price of $657.57.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $693.98 on Thursday. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $256.60 billion, a P/E ratio of 37.33, a P/E/G ratio of 2.87 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $705.79. The stock has a 50 day moving average of $642.42 and a 200-day moving average of $552.67.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.40 by $0.28. The company had revenue of $12.14 billion during the quarter, compared to analysts' expectations of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. Thermo Fisher Scientific's quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the company posted $5.79 EPS. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.